loading
Precedente Chiudi:
$253.54
Aprire:
$261.82
Volume 24 ore:
3.11M
Relative Volume:
4.49
Capitalizzazione di mercato:
$36.68B
Reddito:
$2.25B
Utile/perdita netta:
$-278.16M
Rapporto P/E:
-130.57
EPS:
-2.17
Flusso di cassa netto:
$-42.59M
1 W Prestazione:
+17.20%
1M Prestazione:
+13.07%
6M Prestazione:
+3.45%
1 anno Prestazione:
+93.25%
Intervallo 1D:
Value
$261.00
$289.44
Intervallo di 1 settimana:
Value
$240.94
$289.44
Portata 52W:
Value
$141.97
$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Nome
Alnylam Pharmaceuticals Inc
Name
Telefono
(617) 551-8200
Name
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Dipendente
2,230
Name
Cinguettio
@alnylam
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ALNY's Discussions on Twitter

Confronta ALNY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
283.34 36.68B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.20 129.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
658.48 71.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.02 37.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ONC
Beigene Ltd Adr
251.98 27.10B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-12 Downgrade Wolfe Research Peer Perform → Underperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-08-16 Aggiornamento Goldman Neutral → Buy
2024-02-16 Downgrade Goldman Buy → Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-08 Iniziato Wells Fargo Equal Weight
2023-10-11 Downgrade Oppenheimer Outperform → Perform
2023-09-29 Iniziato Raymond James Outperform
2023-05-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-26 Iniziato SMBC Nikko Neutral
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Buy
2022-09-09 Ripresa Morgan Stanley Equal-Weight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-27 Downgrade Guggenheim Buy → Neutral
2022-06-07 Iniziato William Blair Outperform
2022-04-25 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-03-01 Iniziato Citigroup Buy
2022-02-03 Aggiornamento Guggenheim Neutral → Buy
2022-01-03 Aggiornamento Piper Sandler Neutral → Overweight
2021-11-22 Aggiornamento Goldman Neutral → Buy
2021-11-22 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Aggiornamento Oppenheimer Perform → Outperform
2021-10-04 Aggiornamento UBS Neutral → Buy
2021-08-04 Downgrade Piper Sandler Overweight → Neutral
2021-02-22 Downgrade Guggenheim Buy → Neutral
2021-02-12 Downgrade Citigroup Buy → Neutral
2021-02-12 Reiterato H.C. Wainwright Buy
2021-01-25 Downgrade BMO Capital Markets Outperform → Market Perform
2020-09-30 Ripresa Berenberg Hold
2020-09-08 Iniziato Citigroup Buy
2020-08-11 Downgrade Oppenheimer Outperform → Perform
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2020-05-07 Downgrade JP Morgan Overweight → Neutral
2020-04-24 Ripresa Evercore ISI Outperform
2020-03-19 Iniziato Berenberg Buy
2019-12-19 Reiterato Chardan Capital Markets Buy
2019-11-20 Iniziato Oppenheimer Outperform
2019-11-13 Iniziato BofA/Merrill Buy
2019-05-23 Ripresa Goldman Neutral
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-06 Aggiornamento Evercore ISI In-line → Outperform
2019-03-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-01-23 Iniziato UBS Neutral
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-13 Reiterato Stifel Buy
2018-08-07 Aggiornamento Stifel Hold → Buy
2018-05-04 Reiterato Stifel Hold
2018-03-28 Iniziato Evercore ISI In-line
Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

pulisher
Mar 21, 2025

Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's

Mar 21, 2025
pulisher
Mar 21, 2025

Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes

Mar 21, 2025
pulisher
Mar 21, 2025

Check Out What Whales Are Doing With ALNY - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam prices heart drug at premium to rivals - BioPharma Dive

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.

Mar 21, 2025
pulisher
Mar 21, 2025

BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Pharmaceuticals Recieives US FDA Approval for ATTR-CM Drug -March 21, 2025 at 03:59 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 20, 2025

Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy - CGTLive™

Mar 20, 2025
pulisher
Mar 20, 2025

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - Citeline News & Insights

Mar 20, 2025
pulisher
Mar 20, 2025

US FDA expands approval for Alnylam's drug to treat rare heart disease - Reuters

Mar 20, 2025
pulisher
Mar 20, 2025

Alnylam wins FDA approval for rare heart disease drug - The Business Journals

Mar 20, 2025
pulisher
Mar 20, 2025

FDA approves first dual-action treatment for ATTR amyloidosis - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Amvuttra’s label expansion lifts Alnylam toward five-year goals - BioCentury

Mar 20, 2025
pulisher
Mar 20, 2025

US FDA expands approval for Alnylam's drug to treat rare heart disease -March 20, 2025 at 06:04 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

US FDA approves Alnylam's drug for rare heart condition - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) -March 20, 2025 at 05:57 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

US FDA approves Alnylam's drug for rare heart condition -March 20, 2025 at 05:56 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Free genetic testing for AHP offered by Alnylam Act in US, Canada - Porphyria News

Mar 19, 2025
pulisher
Mar 18, 2025

Alnylam at Stifel’s 2025 CNS Forum: Advances in RNAi for Neurological Diseases - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Alnylam Pharmaceuticals To Present At Stifel 2025 Virtual CNS Forum; Webcast At 3:00 PM ET - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Arbor raises $74M amid genetic medicine’s funding slump - BioPharma Dive

Mar 18, 2025
pulisher
Mar 17, 2025

RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space - BioSpace

Mar 17, 2025
pulisher
Mar 14, 2025

How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum? - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 14, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - BioSpace

Mar 13, 2025
pulisher
Mar 13, 2025

Antisense Oligonucleotides Market reached US$ 2,985.97 - openPR

Mar 13, 2025
pulisher
Mar 13, 2025

Alnylam Pharmaceuticals’ SWOT analysis: strong data bolsters $8B amvuttra potential - Investing.com

Mar 13, 2025

Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$615.02
price up icon 0.32%
biotechnology ONC
$251.98
price down icon 4.04%
$95.38
price down icon 0.88%
$33.70
price up icon 0.60%
$19.75
price up icon 1.59%
Capitalizzazione:     |  Volume (24 ore):